International Business News - TEVA http://www.ibtimes.com All articles are copyrighted by IBTimes.com 400 100 http://www.ibtimes.com/ http://www.ibtimes.com/images/top_logo_ibt2_3.gif Among the stock activity stories for Friday, Sept. 26, from AP Financial News: WASHINGTON (AP)--Shares of F5 Networks were up nearly 6 percent Friday after two analysts upgraded the stock, saying that recent concerns about the company's exposure to the crisis on Wall Street are overblown. http://www.ibtimes.com/articles/20080926/movers-roundup-f5-networks-wachovia.htm Fri, 26 Sep 2008 14:41:57 EDT Shares of Indevus Pharmaceuticals Inc. more than doubled Friday after the company said it is collaborating with Teva Pharmaceutical Industries Ltd. to develop a treatment for stuttering and could move forward with its delayed horomonal disorder drug. http://www.ibtimes.com/articles/20080926/indevus-shares-double-deals-with-fda-teva.htm Fri, 26 Sep 2008 19:24:01 EDT Teva Pharmaceutical Industries Ltd. said Wednesday it will team with Kowa Co. to create a generic drug maker in Japan, a large market where it expects generic use to grow over the next few years. http://www.ibtimes.com/articles/20080924/teva-and-kowa-to-create-japanese-generic-maker.htm Wed, 24 Sep 2008 07:03:58 EDT Teva Pharmaceutical Industries Ltd. said Tuesday the Food and Drug Administration approved its ProAir asthma medication for patients as young as 4 years old. http://www.ibtimes.com/articles/20080923/teva-asthma-drug-approved-for-children-4-to-11.htm Tue, 23 Sep 2008 16:47:03 EDT Big pharmaceutical companies and their biotech cousins will likely weather the financial crisis engulfing Wall Street, several analysts said, because of the necessity of their products and cash-rich balance sheets. http://www.ibtimes.com/articles/20080923/sector-snap-drug-developers-insulated-from-storm.htm Tue, 23 Sep 2008 14:28:34 EDT A Wachovia analyst upgraded the generic drug sector on Monday, and raised his ratings on Teva Pharmaceutical Industries Ltd. and Watson Pharmaceuticals Inc. because they are trading at discounts to their peers. http://www.ibtimes.com/articles/20080922/ahead-of-the-bell-generic-drug-makers.htm Mon, 22 Sep 2008 09:18:29 EDT A wave of consolidation that has reshaped the generic drug industry in recent years will continue, experts say, as companies like Teva Pharmaceutical Industries and Mylan Inc. compete for new business in emerging global markets. http://www.ibtimes.com/articles/20080919/more-consolidation-seen-in-generic-drug-industry.htm Fri, 19 Sep 2008 16:20:02 EDT Citigroup Inc. named former Lehman Brothers executive Mark Shafir as its head of mergers and acquisitions unit on Thursday. Shafir was chairman and co-head of Mergers and Acquisitions at Lehman, which filed for bankruptcy protection on Monday. http://www.ibtimes.com/articles/20080918/citi-names-lehman-exec-to-run-merger-department.htm Thu, 18 Sep 2008 15:43:04 EDT Expanding the use of low-cost generic pharmaceuticals would be near the top of the health care agendas of both Barack Obama and John McCain if elected in November, advisers for the presidential contenders said Thursday. http://www.ibtimes.com/articles/20080918/obama-mccain-advisers-agree-on-generic-drugs.htm Thu, 18 Sep 2008 14:23:31 EDT Shares of drug developer Mylan Inc. rose Wednesday following the Food and Drug Administration's move to ban imports from the company's generic competitor Ranbaxy Laboratories. http://www.ibtimes.com/articles/20080917/mylan-shares-rise-as-rival-ranbaxy-gets-fda-ban.htm Wed, 17 Sep 2008 19:47:15 EDT Among the premarket activity stories for Tuesday, Sept. 16, from AP Financial News: NEW YORK (AP)--Regulated utilities remain an attractive investment in a low-interest rate environment given expected net income growth of up to 9 percent, a Goldman Sachs analyst said Tuesday. http://www.ibtimes.com/articles/20080916/premarket-roundup-utilities-wabco-holdings.htm Tue, 16 Sep 2008 10:18:58 EDT Drug maker Mylan Inc. said Tuesday the Food and Drug Administration has approved its generic version of the anti-psychotic Risperdal, and the company plans to start selling the drug soon. http://www.ibtimes.com/articles/20080916/mylan-says-fda-approves-its-generic-risperdal.htm Tue, 16 Sep 2008 08:45:26 EDT Shares of generic drug developer Watson Pharmaceuticals Inc. could be ready for a downturn, while rivals Teva Pharmaceutical Industries Ltd. and Mylan Inc. are in more stable positions, according to Goldman Sachs. http://www.ibtimes.com/articles/20080916/ahead-of-the-bell-generic-drug-developers.htm Tue, 16 Sep 2008 08:11:22 EDT Generic drug maker Teva Pharmaceutical Industries Ltd. has lost 180-day exclusivity for its version of the anti-psychotic drug Risperdal, which could allow Teva's rivals to begin selling their own generics. http://www.ibtimes.com/articles/20080915/teva-says-it-has-lost-exclusivity-on-risperdal.htm Mon, 15 Sep 2008 10:42:58 EDT Federal regulators are seeking additional information about Teva's plan to buy generic drug rival Barr Pharmaceuticals. The $7.5 billion deal, announced in July, would cement Israel-based Teva's role as the largest generic drugmaker in the world. http://www.ibtimes.com/articles/20080903/ftc-seeks-more-information-on-tevas-barr-takeover.htm Wed, 03 Sep 2008 15:02:35 EDT Drug developer Teva Pharmaceutical Industries Inc. spent $490,000 in the second quarter to lobby on various generic drug and federal reimbursement issues, according to a recent disclosure form. http://www.ibtimes.com/articles/20080828/teva-pharmaceutical-spent-490k-lobbying-in-2q.htm Thu, 28 Aug 2008 12:47:09 EDT Teva Pharmaceutical Industries Ltd. said Tuesday its drug Azilect slowed the progression of Parkinson's disease and reached all its goals in a late stage clinical trial. http://www.ibtimes.com/articles/20080826/teva-says-azilect-slows-progression-of-parkinsons.htm Tue, 26 Aug 2008 08:33:06 EDT Generic drug maker Barr Pharmaceuticals Inc. spent over $1.5 million lobbying on legislation affecting the drug industry in the second quarter, according to a recent disclosure form. http://www.ibtimes.com/articles/20080811/barr-pharmaceuticals-spent-1-5m-lobbying-in-2q.htm Mon, 11 Aug 2008 15:05:25 EDT Shares of Par Pharmaceutical Cos. plunged Friday after the generic drug developer reported a second-quarter loss and slashed its outlook because of tougher competition and pricing pressure. http://www.ibtimes.com/articles/20080808/par-pharma-shares-dive-on-2q-loss-outlook-cut.htm Fri, 08 Aug 2008 11:07:46 EDT Generic drug maker Barr Pharmaceuticals says its second-quarter earnings rose 27 percent on higher product sales. New Jersey-based Barr says profit rose to $57 million, or 52 cents per share, compared with $45 million, or 41 cents per share, for the same quarter last year. Adjusted earnings were 64 cents per share. http://www.ibtimes.com/articles/20080807/barr-pharmaceuticals-reports-2q-profit-increase.htm Thu, 07 Aug 2008 08:02:03 EDT